Cybin Inc. (CYBN) closed the last trading session at $9.53, gaining 4.4% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street ...

Cybin Inc. (CYBN) closed the last trading session at $8.46, gaining 7.1% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street ...

Cybin ( (TSE:CYBN)) just unveiled an announcement. On December 30, 2025, Cybin Inc. launched an at-the-market (ATM) equity program allowing it to issue and sell up to US$100 million of common shares ...

On Thursday, H.C. Wainwright analyst Pat Trucchio adjusted the price target for Cybin Inc. (NYSE:CYBN) stock, lowering it to $150.00 from the previous $190.00 while maintaining a Buy rating on the ...

Guggenheim has initiated its coverage of psychedelic drug developer Cybin (NYSE:CYBN) with a Buy rating and a $35 per share target, indicating that the company’s lead asset, CYB003, can one-day rival ...

We recently compiled a list of the 12 Best Psychedelic Stocks to Buy in 2025. In this article, we are going to take a look at where Cybin Inc. (NYSEAMERICAN:CYBN) stands against the other psychedelic ...

We recently compiled a list of the 13 Best Psychedelic Stocks to Invest in Now. Cybin Inc. is one of them. Cybin Inc. (NYSE:CYBN) is a clinical-stage neuropsychiatry company developing ...

The United States Patent and Trademark Office (USPTO) has granted U.S. patent 12,122,741, which claims the composition of matter of lead preclinical candidates in Cybin Inc’s (NYSE:CYBN) CYB005 ...

Cybin (NYSEMKT:CYBN) just reported results for the fourth quarter of 2023. Cybin reported earnings per share of -1 cent. This was above the analyst estimate for EPS of -4 cents. The company did not ...